Incyte | INCY - Gross Profit On Sales


Incyte reported $1.57B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agenus USD 33.74M 468K Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novartis USD 10.07B 758M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026